These changes remained statistically significant when adjusting for weight loss, which may suggest weight loss independent effects, potentially implicating direct surgical effects in youth-onset type 2 diabetes such as incretin responses, arguing for more pediatric studies of GLP-1 and other incretin medications. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.